A Road Map To Expedited Review Pathways

Accelerated development and manufacturing timelines provide developers with paths to move new therapies to market quickly while still maintaining a balance of risk/benefit assessment for patients. 

Regulatory agencies around the world (e.g., FDA, EMA, PMDA, NMPA) offer expedited approval pathways that are applicable when new products are filling unmet medical needs for certain targeted diseases or conditions

These accelerated regulatory pathways shorten timelines for therapies addressing serious conditions and unmet need, but add complexity across CMC, clinical supply, and regulatory planning. Integrated project management and consultancy from an experienced CRDMO can help anticipate regulator expectations, manage supply chain constraints, and keep programs on course as requirements evolve.

This expert‑led whitepaper outlines practical questions sponsors can use to assess pathway fit. Quotient Sciences' experts highlight considerations across global agencies, and emphasize early alignment of target product profile, control strategy, resources, and risk mitigation under compressed timelines. 

Download "A Road Map To Expedited Review Pathways" to read how Quotient Sciences helps clients navigate the development pathway to meet regulatory requirements and generate the data needed to support drug approval.